HER-Seq: A blood-based genomic screening study to identify HER2 mutation-positive patients for enrollment into clinical trials with the pan-HER inhibitor neratinib-MedSci.cn

HER-Seq: A blood-based genomic screening study to identify HER2 mutation-positive patients for enrollment into clinical trials with the pan-HER inhibitor neratinib

Tomasevic, Z; Smyth, LM; Saura, C; Boni, V; Garcia-Saenz, JA; Prat, A; Eli, L; Garza, SJ; Lalani, AS; Crown, JP

ANNALS OF ONCOLOGY, 2019; 30 ():

科室
- - 订阅+
  - 更多科室
工具
服务